Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 ...
Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma -SEATTLE, April 27, 2026 (GLOBE ...
The MarketWatch News Department was not involved in the creation of this content. Highlights the continued expansion of the diagnostic capabilities of the PanGIA Analysis System to include oral cancer ...
Reflecting the Company's continuing research into expanding the capabilities of the PAS across early detection applications, the accepted abstracts include: PanGIA Analysis System, a novel machine ...
State Street SPDR S&P Biotech ETF (XBI) and iShares Biotechnology ETF (IBB) have delivered strong returns of 40.80% and 33.95% respectively over the trailing year, but their equal-weight versus market ...
Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...
Biotech has benefited marginally from this rotation. Value beat growth notably in the first quarter. The energy sector was obviously the best performing of the 11 sectors of the S&P 500 in Q1 with a ...
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...
Marc Cummings, president and CEO of Life Science Washington, speaking at a one-day forum focused on AI-driven biotech that was held in Seattle in October 2025. (Life Science Washington Photo) Seattle ...
When Gossamer Bio announced poor results from its flagship blood pressure study in February, the San Diego company’s stock dropped by 78% in value. Now, it’s slashing its staff. The biotech lab began ...
Over the last couple of weeks, the biotech and pharma spaces have been inundated with product launches, partnership announcements, grant awards and breakthrough publications. Here, we highlight an AI ...
Biotech stocks saw a major rebound in 2025, with key indexes significantly outperforming the S&P 500. Private investment in longevity science doubled in 2024, highlighting growing interest in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results